If and when the first shareholder lawsuit is filed against Navidea, it will be my mission and purpose to encourage any and all Navidea shareholders to sue each of you PERSONALLY. You have cheated and harmed the Navidea investor with your CONSTANT incompetence, mismanagement, inaction, dereliction of job responsibilities as a matter of policy, and absolute disregard for shareholders.
National attention needs to be focused on the harm you daily do to your own investors. Perhaps those that bought your garbage stock on the TASE exchange will be the first to sue you personally and the company itself.
STOP THE NONSENSE NOW!
Post # 7306 on IHUB Navidea board (wasn't too far off):
An article to be released not too far in the future?
MEDICAL NEWS TODAY
March 19, 2016
"LYMPHOSEEK, the treatment that never was"
Three years ago, Navidea (formerly Neoprobe) gained FDA approval for Tilmanocept-99, specifically designed and indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma. Since March 2013 though, sales have only amounted to $9.3 million as the medical community worldwide has simply not taken to the product. "I just don't know what to make of it," said Allen Richards (Navidea's seventh CEO in the past three years) "We were so sure it would become the standard of care. In the end, all we did was fleece investors and create angry shareholders." Brent Larson, a long time Navidea employee was terminated and jailed in 2015 after it was revealed that he had illegally been feeding insider information to numerous large short sellers of the company for years, albeit to the company's near bankruptcy at present. With 375,000,000 shares outstanding from five new share offerings since the September 2013 Crede deal, and a current share price of .09, the future of this tiny biotech is more in doubt than ever.
institutions could be buying all they want under 1.00.
Yet, they don't seem to be - and neither are shorts covering. Uh oh.
Very good question - and it seems remarkable that such hasn't happened yet. Navidea management is screwing with people's lives and portfolios. They can't sell Lymphoseek, but they can sure make any Navidea investment disappear. I was almost expecting a 90,000,000 share offering this morning "priced at .40 per unit" compliments of Crede. Maybe tomorrow...
This is a very good question. Any short is up considerably when NAVB is trading at or below 1.00 AND THEY ARE NOT COVERING? Just how bad have you harmed the company Rick Gonzalez? Shareholders WILL NOT STAND FOR YOUR NONSENSE MUCH LONGER!
STOP THE NONSENSE and START building shareholder value.
PERIOD. This disgusting treatment of shareholders is ruining the company reputation worse than you have already done in 2013, 2014, and 2015!
Brent Larson needs to be fired immediately to save precious cash. His contribution to Navidea has been next to nothing for years. Period.
Just how bad are things going to get? What does Larson know that the rest of us don't yet?
January has historically been very good or great for Navidea and Neoprobe. This January is looking like the beginning of the end.
1.02 today! WHY?!
is Brent Larson's sales of his shares. The fact that he is unloading his entire NAVB holdings at this level is VERY TELLING.
How much more downward pps movement do you need to see to believe it?
You were right about Q4 sales. A letdown. This makes it look like you will also be right about cash flow break even also not happening on schedule.
Can I be labeled as an Oldtimer when I buy my first block of NAVB at .08? It sure looks like that's where this is headed.
company silence across the board doesn't do the job first. Shareholders need to call Gonzalez's office and start screaming. This is unacceptable!
and the complete dumping of Brent Larson's position makes more and more sense.
WHAT WE DON'T KNOW is just how bad the situation is (like Brent Larson did months ago when he arranged the sale of his position 12,500 shares at a time.)
Will Q4 sales be under $4 million? Under $3 million?! A rude sales surprise has become the norm every month. Nothing negative with sales should surprise anyone.
Will MT be delayed until year 2107? Sure as hell seems like it.
Will 4694 be thrown away for next to nothing? Likely. Will it take another 6 months or more for Navidea to throw it away? Probably.
This poor management is not helping the company or the share price.
Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) has lost 5.67% during the past week and dropped 10.74% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 4.89%. Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) has underperformed the index by 8.65% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Navidea Biopharmaceuticals, Inc has dropped 41.41% during the last 3-month period . Year-to-Date the stock performance stands at -29.63%.
Shares of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) ended Thursday session in red amid volatile trading. The shares closed down 0.01 points or 0.75% at $1.33 with 458,401 shares getting traded. Post opening the session at $1.34, the shares hit an intraday low of $1.32 and an intraday high of $1.37 and the price vacillated in this range throughout the day. The company has a market cap of $207 million and the number of outstanding shares have been calculated to be 155,699,670 shares. The 52-week high of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) is $2.495 and the 52-week low is $1.22.
Currently the company Insiders own 2.1% of Navidea Biopharmaceuticals, Inc. shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -10.11% . Institutional Investors own 35.63% of Navidea Biopharmaceuticals, Inc. shares. During last six month period, the net percent change held by insiders has seen a change of -21.95%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The officer (EVP, CFO, Treas & Secy), of Navidea Biopharmaceuticals, Inc., Larson Brent L had unloaded 12,500 shares at $1.5 per share in a transaction on December 1, 2015. The total value of transaction was $18,750.
The lack of insider buys coupled with the lack of any updates at all from the company on MT tells me that they already know MT is garbage and headed no where EVER! The lack of insider buys should concern all shareholders as the pps continues to bleed and drown in typical Navidea style.
This constant abuse and neglect of shareholders by Navidea is becoming quite tiresome. Sure, Martin S. was arrested today. So what! It does nothing to fix all that is wrong with NAVB. That's Rick Gonzalez's job AND HE ISN'T getting it done - just like his 12 member sales team isn't. When the Q4 numbers come out, NAVB goes under 1.00. Wait and see.
The lower NAVB goes, the less Brent Larson gets for his sells. This is the only good thing I see as I follow the daily trading pattern of garbage NAVB.
It is looking like NAVB will not see 2.00 in 2016 - and if it approaches 2.00, I can't imagine the enormous resistance there will be at 2.00 this time.
The TASE listing was a gift to the Oldtimers to let them out without informing the rest of us that this garbage stock was dead. An investigation is warranted. Congratulations to UBD on the Oldtimers board for being out of NAVB altogether!
At the Navidea double deck black jack table, the player loses no matter what their hand is. Black jacks, 21s and 20s demand double surrender of the bet - a Rick Gonzalez special.
At the Navidea Baccarat table, instead of the usual bets of PLAYER and BANKER, the bets have been renamed BANKRUPTCY and SEVERE DILUTION. The banker commission on SEVERE DILUTION winning hands is 20% instead of the usual 5% - this was Brent's idea to take more money than ever from the Navidea investor.
the fact that many longs like myself now see Navidea for what it really is clearer than ever - a company that destroyed their own stock in September 2013 with Crede and has only weakened it further with continual misleading projections and unrealistic forecasts. Even a few IV Oldtimers like alf33 openly post that management leaves much to be desired at present. If I were a short, I'd have covered by now in this range. And wise old DDbuyer hinted that there is an excess of VPs at Navidea not too long ago. Bottom line is, Manocept seems way too big AND worthless at the same time (or the stock would hold 2.00+ regardless of shorting).
No insiders are buying but Brent Larson is selling. Fact. Navidea said in the 10Q that Manocept COULD be spun off in Q1 2017...an eternity when one considers how weak this stock has performed for 27 months now.
The TASE investors got raped. I hope they sue Navidea immediately.
The TASE listing did nothing to help Navidea credibility in regard to treatment of shareholders, only made it worse.
I wish I was a huge Navidea short from the 4.00+ range on down. I'd be set for life...just like Bupp and Pykett are...and how Rick Gozalez will be when he gets his $750K severance. Navidea is way overdue for an update on many fronts. Where is it?